Extended Data Fig. 9: Persistence of high affinity SLAMF6+TSL loss after cessation of checkpoint blockade.
From: Inhibitory PD-1 axis maintains high-avidity stem-like CD8+ T cells
a, Experimental scheme illustrating the checkpoint treatment strategy allowing 9-10 days of recovery after treatment had stopped at Day 10. b, Representative flow cytometry plots of TCF-1 and SLAMF6 expression on OVA-tetramer+ CD8+ T cells in the tdLN at Day 19.5 and the gating strategy defining the three major TSL and TEFF subsets. Mean fluorescence intensity of TCF-1 (c) and SLAMF6 (d) of each subset of OVA-tetramer+ CD8+ T cells, normalized to naïve (CD44- TCF-1+ PD-1-) CD8+ T cells. The total numbers of each subset recovered from the tdLN are shown in (e, f). g, Total number of “high affinity” SLAMF6+ TSL (imputed affinity index >mean of control (PBS-treated) SLAMF6+ TSL from the same experimental cohort) in the tdLN. Standardized log transformed imputed TCR affinity index (h) and mean imputed affinity index (i) of each treatment group, normalized to PBS-treated SLAMF6+ TSL from the same experimental cohort. Data in (b-i) are pooled from 4 independent experiments (n = 13 per treatment group). Error bars: means ± s.d. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; unpaired two-tailed t-test.
